Eli Lilly posts strong Q3 results, raises 2025 outlook, driven by growth in GLP-1 products Mounjaro and Zepbound.
FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.
Trump ends U.S. nuclear-testing moratorium, raising concerns about an arms race and global nonproliferation efforts.
Eli Lilly posts strong Q3 results, raises 2025 outlook, driven by growth in GLP-1 products Mounjaro and Zepbound.
FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.
Trump ends U.S. nuclear-testing moratorium, raising concerns about an arms race and global nonproliferation efforts.